Loading...
Loading...
Browse all stories on DeepNewz
VisitWill the FDA approve Stanford's nanoparticle adjuvant for use in vaccines by December 31, 2024?
Yes • 50%
No • 50%
FDA announcements and official website
Stanford Develops Nanoparticle Adjuvant for Robust, Tunable Vaccine Immune Response
Aug 7, 2024, 06:41 PM
Researchers at Stanford Engineering have developed a new nanoparticle adjuvant that enhances the effectiveness of vaccines by producing more robust, longer-lasting, and tunable immune responses. This advancement, detailed in Science Advances, builds on existing vaccine additives and offers promising improvements in vaccine efficacy. The work by Ou Ben and Julie Baillet is part of ongoing efforts to improve vaccine performance, particularly in the context of COVID-19 and other diseases.
View original story
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
COVID-19 • 25%
Other • 25%
HIV • 25%
Influenza • 25%
Not published • 25%
Positive • 25%
Negative • 25%
Mixed • 25%